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AbstrACt
Introduction Low- income and middle- income settings 
like India have large treatment gaps in mental healthcare. 
People with severe mental disorders face impediments 
to their clinical and functional recovery, and have large 
unmet needs. The infrastructure and standards of care 
are poor in colonial period psychiatric hospitals, with no 
clear pathways to discharge and successfully integrate 
recovered individuals into the community. Our aim is 
to study the impact of psychiatric hospital reform on 
individual patient outcomes in a psychiatric hospital in 
India.
Methods and analysis Structured Individualised 
inTervention And Recovery (SITAR) is a two- arm pragmatic 
randomised controlled trial, focusing on patients aged 
18–60 years with a hospital stay of 12–120 months and a 
primary diagnosis of psychosis. It tests the effectiveness 
of structural and process reform with and without an 
individually tailored recovery plan on patient outcomes of 
disability (primary outcome WHO Disability Assessment 
Scale), symptom severity, social and occupational 
functioning and quality of life. A computer- generated 
permuted block randomisation schedule will allocate 
recruited subjects to the two study arms. We aim to recruit 
100 people into each trial arm. Baseline and outcome 
measures will be undertaken by trained researchers 
independent to the case managers providing the individual 
intervention. A health economic analysis will determine the 
costing of implementing the individually tailored recovery 
plan.
Ethics and dissemination The study will provide 
answers to important questions around the nature and 
process of reforms in institutional care that promote 
recovery while being cognizant of protecting human 
rights, and dignity. Ethical approval for SITAR was obtained 
from a registered ethics committee in India (Institutional 
Ethics Committee VikasAnvesh Foundation, VAF/2018-
19/012 dated 6 December 2018) and the University of 
Warwick’s Biomedical and Scientific Research Ethics 
Committee (REGO-2019–2332, dated 21 March 2019), 
and registered on the Central Trial Registry of India 
(CTRI/2019/01/017267). Trial results will be published 
inaccordance to CONSORT guidelines.
IntroduCtIon
People living with severe mental disorders 
(SMD) (psychosis, bipolar and affective disor-
ders and severe- to- moderate depression) in 
low- income and middle- income countries 
(LMICs) face impediments to their clin-
ical and functional recovery, and have large 
unmet needs associated with poverty, protec-
tion of human rights, social inclusion and 
participatory citizenship.1–5 A range of cost- 
effective and evidence- based interventions 
strengths and limitations of this study
 ► This is the first ever methodologically robust study 
in low- income and middle- income countries to test 
the impact of reforms in a psychiatric hospital on 
important patient outcomes such as change in dis-
ability, symptoms, social and occupational function-
ing and quality of life.
 ► The study offers an individual recovery plan for a 
psychiatric hospital setting in low resource settings.
 ► The cost implication of the individual service pack-
age will be studied; this has relevance in influencing 
mental healthcare policy across the country.
 ► There is a strong component of government involve-
ment that adds to the potential of sustainability and 
scaling up across other psychiatric hospitals in the 
country.
 ► It is not possible to blind the case managers to the 
group allocation due to the nature of the intervention, 
hence it is a single- blind study, with only research-
ers assessing outcomes being blind to allocation.
 ► Given the nature of the setting, there is also a risk of 
contamination across both trial arms.
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are now available, however there are major barriers in 
access to appropriate care, increasing vulnerability and 
disadvantage along with stigma and discrimination.1 2 6–9 
Many languish in large hospitals, abandoned by family 
and forgotten by policy makers. India has 43 psychiatric 
hospitals built during the colonial period that continue 
to function almost in the same way as they did when 
they were set up.10–14 These hospitals constitute 80% of 
all available psychiatric beds.15 At the end of 2015, there 
were 6829 patients staying in 30 of the 43 psychiatric 
hospitals; 16% had been inpatients for >5 years, some 
for three to four decades.5 The infrastructure and stan-
dards of care are poor.14 There are no clear pathways 
to discharge and successfully integrate former patients 
into the community.16 A complex mix of low priority for 
mental healthcare in India, lack of support from central 
and state governments and low autonomy and decision- 
making power among professionals working in such insti-
tutions has impeded any meaningful reform.14
Psychiatric hospitals in India have played an important 
role in the care of very vulnerable people and continues 
to remain a legitimate and relevant locus of care for 
people in need of services.17 Given the lack of feasibility 
of closing down psychiatric institutions in most LMICs, 
there is an urgent need for manageable and evidence- 
based reform of these hospitals. The Udaan programme 
seeks to address this need.
the udaan programme
Udaan is a partnership of Tata Trusts with government 
of Maharashtra, formalised through a Memorandum of 
Understanding, to develop the Regional Mental Hospital 
Nagpur (RMHN) as a centre of excellence through 
systematic reform of the hospital. Maharashtra is a state 
in the Western peninsular region of India with Nagpur 
being right in the centre of the country. Udaan (which 
in Hindi mean ’to soar’) comprises four key reform 
elements: structural (refurbishing old colonial infra-
structure to meet current service user needs), process 
(standardising clinical and non- clinical processes of 
the hospital), capacity building (standard training for 
different levels of hospital staff) and introduction of the 
needs- based intensive case management (NB- ICM), an 
individual need- based, recovery- oriented, service package 
for patients delivered through ICM. The Udaan elements 
are detailed in figure 1.
structured Individualised intervention And recovery
The Structured Individualised inTervention And 
Recovery (SITAR) study is embedded within the Udaan 
programme. In a clinical trial we test whether NB- ICM 
improves patient outcomes among long stay inpatients, 
in comparison to care as usual in a psychiatric hospital 
undergoing reform in an LMIC. The objectives of SITAR 
are:
a. To compare the effectiveness of structural and pro-
cess reform with and without an individually tailored 
recovery plan on patient- level outcomes of disability 
(primary outcome), symptom severity, social and oc-
cupational functioning and quality of life for the long 
stay patient cohort of the hospital.
b. To determine the costing of implementing an individ-
ually tailored recovery plan for long stay individuals in 
psychiatric hospitals.
ICM calls for high resources and as such may not be 
feasible in low- income settings. We thus seek to compare 
patient outcomes emerging from larger structural and 
process reform in old psychiatric hospitals as compared 
with patient outcomes when ICM is added along with the 
reform. This comparison has significant value in policy 
decision making on how meagre resources should be 
used in low resource settings where mental healthcare 
continues to be provided by psychiatric hospitals set up 
100 to 200 years ago.
This paper presents the protocol of SITAR, which aims 
to bridge a critical gap in scientific evidence by studying 
the impact of reform of psychiatric hospitals on individual 
patient outcomes. The findings will provide an evidence- 
based package of reforms for psychiatric hospitals in tran-
sition in LMICs.
MEthods And AnAlysIs
study design and management
The study is a pragmatic parallel- arm single- blind 
randomised controlled trial at a single site, the RMHN. 
The psychiatric hospital in Nagpur was started in 1864. 
The hospital has a capacity of 940 beds with an average 
occupancy of 600 patients at any given time.
Recruitment of patients for the study was initiated 
after completion of permissions, ethics approval and trial 
registry. We will continue recruitment till adequate sample 
size (85 in each arm) is reached. This is a changing popu-
lation with a constant process of admission and discharge 
to the hospital. We assume a 6 months time frame to 
complete full recruitment from the start of intervention.
The inpatient population of the hospital will be 
compiled on a database, mapping sociodemographic 
variables, history of illness and history of treatment as 
baseline data. Patients fitting the inclusion criteria will be 
identified and randomly assigned to the intervention and 
control arms of the study. Recruitment will be continued 
till desired numbers are reached. The intervention will 
be carried out for a 6- month period. Postmeasures on all 
patients who have undergone premeasures will be under-
taken at completion of intervention (at 6 months) and 
at two follow- up intervals postintervention of 9 and 12 
months (3 and 6 months after completion of interven-
tion). The SITAR study design is presented graphically 
in figure 2.
Several steps are proposed to ensure quality control 
and minimise the risk of bias:
1. Use of a standard case management intervention (in-
tervention manual developed for the study).
2. Randomisation of the sample to intervention and care 
as usual arms of the study.
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Figure 1 Graphic representation of Structured Individualised inTervention And Recovery (SITAR).
3. Outcome measurements will be undertaken by re-
searchers independent of the case managers deliver-
ing the intervention. Inter- rater reliability for the re-
searchers will be computed. The statistician drawing 
the randomisation tables will be blinded to the alloca-
tion of the groups.
4. Each case manager will be supervised at least once ev-
ery month on at least 20% of the cases undertaken by 
them. Joint monthly meetings of all case managers will 
be held for case reviews and sharing of experiences 
and discussion on overcoming barriers.
5. The primary supervisor will conduct a site visit and meet 
the case managers to assess fidelity of intervention.
Given the nature of the setting, there is a risk of contam-
ination across arms especially since the hospital staff 
providing care in both arms are the same. We believe this 
is a minimal possibility given the meagerness of engage-
ment of hospital staff with the patients.
SITAR is part of the work done by the first author in 
fulfilment of the PhD programme at the University of 
Warwick. The study will be coordinated by the Udaan 
office located at RMHN. The study is managed by the 
PI with supervision from the supervisors and oversight 
by the Trial Management Committee (TMC). The TMC 
comprises members from the University of Warwick and 
mental health experts from India.
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Figure 2 Graphic representation of Udaan and Structured Individualised intTervention And Recovery (SITAR)
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Participant eligibility and recruitment
Inpatients at baseline will comprise all service users 
admitted to RMHN. Patients meeting the inclusion 
criteria for the study will be randomised to the two arms 
of the study. Service users will be eligible if they have a 
primary diagnosis of psychosis (schizophrenia, bipolar 
affective disorders and psychosis not otherwise specified) 
based on diagnosis given in their case files, a continued 
length of hospital stay between 12 and 120 months and 
are over the age of 18 years. Service users will be excluded 
from the study if they are over the age of 60 years, have a 
neurodevelopmental disorder such as epilepsy, an intel-
lectual disability or are service users in acute and forensic 
wards.
sample size
For the study to be powered at the 90% level with 5% 
significance level, the required sample is 170 people, 85 
in each arm. Assuming a 15% dropout, we aim to recruit 
100 people in each arm of the study. For the power calcu-
lation, the estimated sample size allows us to detect a 
minimum clinical difference of 10 points in the primary 
outcome (WHO Disability Assessment Scale (WHODAS)) 
at 6 months with an SD of 20. This equates to a moderate 
effect size of 0.5.18 The parameter estimates to inform the 
sample size were drawn from an Indian study based in the 
community with non- ICM using the WHODAS score as 
the primary outcome measure.19 People with psychosis in 
institutional set- ups might have higher disability levels as 
compared with people living in the community, however 
most people in LMICs continue to remain in institutions 
due to the absence of viable pathways of community rein-
tegration. The intervention being offered is intensive 
with longer case management time than what would be 
feasible in a dispersed community setting.
Informed consent
The treating psychiatrist will assess the service users’ ability 
to participate in the study as well as ability to consent. 
The psychiatrist will provide consent for those patients 
unable to give consent but deemed appropriate for the 
intervention. This is especially important in the case of 
this intervention since it is a ‘need- based’ psychosocial 
intervention. Based on inability to consent, patients who 
may need the intervention most might actually be left 
out of the study. The consent by the treating psychiatrist 
will ensure equitable inclusion. Additionally, the ward in 
charge also signs off on the consent. The study will be 
explained pictorially to the service user with the aid of 
a specially designed flip chart. Signatures and/or thumb 
impressions will be taken on simple consent forms drawn 
up in Hindi and Marathi. Service users will be assured 
that their refusal to participate/consent to the study will 
have no impact on the care they receive.
randomisation
The study will use a computer- generated permuted block 
randomisation schedule for the allocation of recruited 
subjects to the two study arms. The researcher will create 
a list of service users meeting the inclusion criteria and 
consenting to the study and give them a unique ID 
number. This list will be handed over to the statistician 
who is independent to the research team. Random allo-
cation of eligible study subjects to two study arms (A and 
B) will be done by the statistician using ralloc software 
(V.3.7.6) available in STATA (V.10.1, 2011) module.
Intervention
The NB- ICM for people living with SMD is based on a 
psychosocial rehabilitation model that takes a holistic 
approach to improving quality of life, reducing disability, 
improving role function, promoting independence and 
autonomy based on a hope for the future. It is a mix of 
working on individual competencies in the context of real 
everyday experiences and introducing environmental 
change propelled by individual choice.20–27
Trained case managers will deliver the intervention 
through a clinical and ICM approach that taps into a func-
tional network of a spectrum of services being created at 
the hospital level through the reform process.
The case managers are trained on a specially designed 
training module that comprises content around severe 
mental illness and ICM with a focus on the needs of 
people with high disabilities in psychiatric institutions. 
The 60 hours training module was delivered through 
7 days of offsite training for the purpose of this study.
The intervention components comprise (1) accom-
modation, safety and food (this is contextualised to the 
hospital setting where all service users may not have access 
to clean living spaces and enough food); (2) psychoedu-
cation (about the illness and its symptoms); (3) symptom 
management; (4) physical health; (5) emotional well- 
being; (6) self- care and other living skills; (7) social 
relationships; (8) connecting with family; (9) leisure 
activities; (10) occupational and financial inclusion and 
(11) spiritual needs.
The intervention is based on an objective assessment of 
current needs of the service user and provides a compre-
hensive package of services to meet the range of individual 
needs. The case manager works collaboratively with the 
person in developing a personalised care plan drawing 
from the larger context of available opportunities within 
the hospital, created through the ongoing reform process. 
The care plan adjusts to the patient’s cultural context. It 
draws on the strengths and potential of the individual 
and is focused on the reduction of personal distress and 
disability. Care provided through this approach is contin-
uous and consistent for the defined period of the inter-
vention. Case managers have the primary responsibility 
for planning, coordinating and delivering the care. Each 
case manager will have a caseload of 12–14 service users 
and spend at least eight sessions per case per month. The 
case manager will deliver the intervention face- to- face 
either in the ward complex or through calls and home 
visits in case the person is discharged from hospital as per 
protocol.
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The intervention will aim:
 ► To address unmet needs on symptomatology through 
appropriate pharmacological management and 
psychosocial support. It also includes diminishing 
and eliminating wherever possible the adverse phys-
ical and behavioural consequence of symptom 
management as well as those arising out of prolonged 
institutionalisation.
 ► To address unmet basic needs of adequate accommo-
dation and food.
 ► To address unmet needs on personal functioning, 
improving activities of daily living both in terms of 
skills and access to opportunities.
 ► To address unmet needs of social connectedness, 
engagement, leisure and social competence through 
individual competency building and access to envi-
ronmental opportunities.
 ► To address unmet needs for personal identity and 
citizenship.
 ► To address the unmet needs of occupational func-
tioning, employment and financial inclusion.
 ► To address the unmet needs of connecting to family 
and community where feasible.
Patients in the control arm will go through the same 
baseline and follow- up measurements as the intervention 
arm. This group will however not receive the NB- ICM 
during the trial period, the control arm will continue 
receiving care as usual, in this case care being provided 
in a setting undergoing reform. In most psychiatric hospi-
tals in India, care as usual largely comprises biomedical 
management.14 28
The intervention will be discontinued given the 
following conditions: (1) if the participant wants to 
discontinue participation; (2) an acute illness episode 
that significantly disrupts time in intervention (beyond 
4 weeks); (3) when the participant is discharged from 
the hospital and community- based intervention is not 
possible either due to distance beyond Nagpur district, 
unwillingness of participant or family for home- based 
intervention; (4) in case of death of a participant.
Adverse events: recording and reporting
Given the nature of the study population and the chro-
nicity of the illness certain events are expected. The study 
protocol classifies these events under ‘adverse events’ and 
‘serious adverse events’. Adverse events comprise (a) acute 
illness (psychosis) episodes as determined by transfer to 
acute ward; (b) episodes of isolation and restraint; (c) 
transfer for medical care outside the psychiatric hospital; 
(d) absconding from the facility. Serious adverse events 
comprise (e) episode of self- harm and (f) death.
To record and report adverse events, we will use the 
Warwick CTU’s Clinical Trials Standard Operating Proce-
dure 17 part 2 Safety Reporting for Clinical Trials other 
than those of Investigational Medicinal Products V.1.5.
Any adverse event occurring with any participant will be 
first notified and discussed with the ward in charge. Based 
on routine hospital care processes, it is the responsibility 
of the ward in charge to initiate action of either directly 
providing any care, making a psychiatric referral or 
making a medical referral. All recorded adverse events 
will be reported to the core committee and the trial super-
visor through monthly reports. These reports will also be 
submitted to the TMC. Any unexpected adverse event will 
be reported to Tata Trusts (as the sponsor) along with the 
India ethics committee, the Central Trial Registry of India 
as well as the university ethics committee (BSREC) within 
15 days of the event.
Measurements
The study comprises outcome measures and process 
measures. Other baseline measurements include sociode-
mographic details, illness history and treatment history.
Outcome measures
Assessment of level of disability will form the primary 
outcome for the study. WHODAS V.2.0, a generic assess-
ment instrument for health and disability that produces 
standardised disability levels and profiles applicable 
across cultures and diseases.29 SITAR will use the simple 
scoring format sufficient to describe the degree of func-
tional limitation.29 Three items of WHODAS are not appli-
cable for scoring due to the nature of the setting. These 
are items 3.4, 4.5 and 6.6. Secondary outcome measures 
include an assessment of severity of symptoms, assessment 
of social and occupational functioning and assessment of 
quality of life. The scales used for these measurements 
include the symptom measure—The Clinical Global Improve-
ment Scale (Schizophrenia) (CGI- S), a brief, stand- alone 
assessment of the clinician’s view of the patient’s global 
functioning prior to and after initiating a study medica-
tion or intervention.30 The CGI comprises two one- item 
measures evaluating (a) severity of psychopathology from 
1 to 7 and (b) change from the initiation of treatment on 
a similar 7- point scale.31 Social and Occupational Functioning 
Scale assesses individual’s level of social and occupational 
functioning and is not directly influenced by the overall 
severity of the individual’s psychological symptoms.32 33 
Health- related quality of life measure EuroQol- 5D (EQ- 5D) is a 
widely used generic patient- reported outcome question-
naire designed specifically for cost- utility economic evalu-
ation internationally. The EQ- 5D asks patients to indicate 
whether they have no, some or extreme problems on each 
of five dimensions of health: mobility; self- care; usual 
activities; pain/discomfort and anxiety/depression.34 35
Process (intervention) measurements include the assess-
ment of need through a standard form based on Camber-
well Assessment of Need.36 The adaptation draws from 
prior use of this measure in India through the formative 
study of needs37 and need assessment formats used in 
community setting.38 This will be carried out by the allo-
cated case managers five times during the study period 
and will be an indicator of the number of met and unmet 
needs of the service user at different points during the 
study. The intervention plan, case managers will draw up 
a personal care plan collaboratively with the service user 
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Table 1 List and time frame for assessments (6 months considered from date of first intervention)
Months
Assessment Type By 0 1 2 3 4 5 6 7 8 9 10 11 12
WHODAS (disability) OM RA ● ● ● ●
SOFS OM RA ● ● ● ●
CGI (symptoms) OM RA ● ● ● ●
EQ- 5D (quality of life) OM RA ● ● ● ●
Episodes of seclusion and restraint OM CM ● ● ● ● ● ● ● ● ● ● ● ● ●
Discharge/adverse events OM CM ● ● ● ● ● ● ● ● ● ● ● ● ●
Needs assessment PM CM ● ● ● ● ●
Intervention plan PM CM ● ● ● ● ● ● ●
Symptoms checklist PM CM ● ● ● ● ●
Self- care and other living skills checklist PM CM ● ● ● ● ● ● ●
Case management record form PM CM ● ● ● ● ● ● ●
●, intervention time frame; CGI, Clinical Global Improvement Scale; CM, case manager; EQ- 5D, EuroQol- 5D; OM, outcome measure; PM, 
process measure ; RA, research assistant; SOFS, Social and Occupational Functioning Scale; WHODAS, WHO Disability Assessment Scale.
and the ward in charge on a monthly basis. Case managers 
will record the plan on a standard form developed for 
the intervention and reviewed monthly by the researcher. 
The symptoms checklist has been adapted from ones used 
in other Indian settings and will record the change in 
symptoms over the study period and serve as an adjunct 
to the symptom measure (CGI). The case manager will 
carry out the measure five times during the study period. 
Self- care and other living skills checklist is adapted to an 
institutional setting from scales for assessing activities of 
daily living.39 40 Its purpose is to aid the case manager in 
assessing progress on the intervention plan.
Baseline and follow-up measurements schedule
Baseline measurements will be initiated at the start of the 
study and completed for all inpatients over a 3- month 
period by trained research assistants (RA) who have a 
Master’s degree in Psychology or Social Work RAs are 
not involved in the hospital setting, however unmasking 
is possible and we will record all episodes of unmasking. 
Inter- rater reliability will be established for all the RAs 
conducting the measurements.
The intervention will be initiated after completion of 
the baseline measurements and carried out for a period 
of 6 months. At the end of the 6- month intervention 
period, the first outcome measurement will be initiated 
and completed over a 2- month period. The first and 
second follow- up outcome measurements will be initi-
ated at 3 and 6 months postintervention, respectively, and 
completed over a 2- month period.
The patient sequence will be kept standard for the 
measurements to ensure uniformity in time between 
measures. In case of an adverse event where the patient 
may not be available for measurement as per sequence, 
accommodation will be made to complete the measure 
any time during the 2- month period of that measure-
ment cycle. In case this is not possible, the patient 
will be considered as lost to follow- up. Sequence and 
time frame of measures are summarised in table 1. 
All patients (except dropouts as per criteria) will be 
followed up as per protocol either within the hospital or 
in the community.
Qualitative element of the study
The qualitative component of the study comprises patient 
perceptions on the overall reform process and the indi-
vidual intervention and its felt impact. The SITAR study 
will use focus group discussions (FGDs) to elicit this. Four 
FGDs of 8 patients each (16 patients from each study 
arm) will be conducted in the last quarter of the study 
period. Since we seek to understand the lived experience 
of the service user, a phenomenological epistemological 
perspective is proposed. A basic thematic analysis will be 
done using NVivo.41 Verbatim quotes will also be used to 
highlight findings from quantitative components of the 
study.
data management and analysis
Data collection
Quantitative data will be collected by trained RAs using 
predesigned, pretested tools as included in the protocol. 
Senior RA will check completeness and accuracy of data 
gathered on daily basis before electronic data entry.
Data storage
The paper data will be stored in secure cabinets, in the 
PI’s cabin at the Tata Trust office in the hospital campus. 
The office is under CCTV surveillance. The data will be 
held for 10 years postcompletion of the study.
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Data entry and coding
Data will coded and entered in an efficient database using 
MS Excel. Data will be kept confidential and anonymous 
on password- protected files. The master sheet will be kept 
separately on MS Excel with password protection. Built in 
validity, checks will be incorporated in data entry software 
with flash/warning alerts for incorrect or out of range 
values.
Data screening, data validation and data editing
Data will be screened at every stage, that is, prerandomi-
sation, postrandomisation and closing stage of the trial. 
This will be done for each and every item of the indi-
vidual record by student researcher (trial PI). Accuracy of 
electronic data will be checked through comparison with 
questionnaire data on a sample basis.
Data analysis
All results from the trial will be reported according to the 
Consolidation Standards of Reporting Trials (CONSORT) 
guideline for randomised controlled trials.42 Descriptive 
statistics will be presented for participant characteristics 
and outcomes collected in the trial summarised by treat-
ment arm. Continuous outcomes will be summarised as 
mean and SD, categorical data will be summarised using 
frequency and percentage. If data are non- normal, the 
median and IQR will be presented.
All of the analyses will be based on the intention- to- treat 
principle, where a p value <0.05 will be considered as 
statistically significant. The primary analysis will estimate 
the treatment effect and 95% CI for the primary outcome 
(WHODAS) at the 6- month time point using a linear 
regression model having adjusted for clinically important 
baseline variables. For all secondary analyses, treatment 
effects will be estimated using adjusted linear regression 
models for continuous outcomes and adjusted logistic 
regression models for binary outcomes. The analyses will 
be undertaken at each of the follow- up time points (ie, 
6, 9 and 12 months). Where the assumption of normality 
is not valid, equivalent non- parametric alternatives (eg, 
rank- based statistics) will be used.
Every effort will be made to ensure that missing data are 
kept to a bare minimum in the trial. The level or extent 
of missingness in data will be assessed at the end of the 
trial, and if required, additional sensitivity analyses will 
be undertaken using multiple imputation techniques to 
impute the missing values.
Data processing
Data will be processed by the Udaan programme at base-
line (prerandomisation), during trial (postrandomisation) 
and closing stage (outcome assessment). Raw data from the 
master file will be coded and processed into a data file. The 
entire data set will be put through an Excel- based double 
entry process by two independent people. Formula- based 
comparison of the two sets will be undertaken and discrep-
ancies will be resolved by rechecking with the hard copy of 
the questionnaire on file. The data file will include both 
original variables as well as some newly derived variables or 
transformed variables specific to the study objectives. Statis-
tical Package of Social Sciences will be used for data analysis. 
The data analyst will be blinded to treatment assignment.
Anonymising data
Direct identifiers that allow the identification and commu-
nication with an individual participant will be removed. 
The names of all participants will be replaced with a master 
list identity (ID) number. The master list containing the ID 
number will be kept with the PI on a password- protected 
file, which will be housed in a password- protected firewalled 
system. The data set for analysis will not include any email 
address, telephone numbers or home address of patients 
(where available). Quasi identifiers such as ward numbers 
will be removed from and variables such as date of admis-
sion and date of discharge will be generalised into length 
of stay.
PAtIEnt And PublIC InvolvEMEnt
FGDs are built into the design of the programme to 
incorporate the patient experience of intervention. No 
patients were involved in the study design.
CostIng And PotEntIAl EConoMIC gAIns of thE 
IntErvEntIon
The SITAR study will also include a retrospective 
bottom- up cost analysis of the individualised interven-
tion in terms of resource or input requirement along 
with costing of resources for care as usual. Cost elements 
will include all the resources used in development of 
the intervention and training material, costs of training, 
costs of intervention delivery which will include staff 
time and costs of supervision (people, facilities, equip-
ment and supplies). The costing will be based on actual 
expenditure incurred through the Udaan programme 
as well as costs components derived through collabora-
tion which include costs of items received in kind such 
as clothes, soaps and shampoos directly linked to patient 
care. Actual government spending on patient care will 
also be done. Costing will be appropriately apportioned 
to the SITAR study in terms of time allocation of staff 
based on an analysis of case management records. Given 
the scope of the study, costs will primarily be presented 
alongside measures of benefit listed in table 1 in the 
form of a cost- consequence analysis.43 A secondary cost- 
effectiveness analysis will additionally be performed in 
which the trial primary outcome will be the measure of 
effectiveness.44
Ethical approval and dissemination
Ethical approval for SITAR has been obtained from 
a registered ethics committee in India (Institutional 
Ethics Committee VikasAnvesh Foundation, VAF/2018-
19/012 dated 6 December 2018) and the University of 
Warwick’s Biomedical and Scientific Research Ethics 
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Committee (REGO-2019–2332, dated 21 March 2019), 
and registered on the Central Trial Registry of India 
(CTRI/2019/01/017267).
Findings of the study will be presented through scientific 
publications as well as through a national- level dissemina-
tion in India along with presentations in different confer-
ences. We also intend to do a policy paper recommending 
a feasible reform process for psychiatric hospitals in India. 
Trial results will be published in accordance with CONSORT 
guidelines.
CurrEnt trIAl stAtus
Recruitment of patients was initiated in April 2019. 
Recruitment was closed in December 2019. The final 
patient recruited will reach end point follow- up in 
December 2020.
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